1. Home
  2. REED vs RNTX Comparison

REED vs RNTX Comparison

Compare REED & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

REED

Reed's Inc.

N/A

Current Price

$3.58

Market Cap

42.8M

Sector

N/A

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
RNTX
Founded
1987
2001
Country
United States
United States
Employees
44
10
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.8M
47.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REED
RNTX
Price
$3.58
$1.04
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
9.9K
685.2K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.74
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$1.00
52 Week High
$5.97
$2.22

Technical Indicators

Market Signals
Indicator
REED
RNTX
Relative Strength Index (RSI) 46.96 31.67
Support Level $3.50 N/A
Resistance Level $4.35 $1.36
Average True Range (ATR) 0.42 0.19
MACD -0.07 -0.09
Stochastic Oscillator 41.67 1.36

Price Performance

Historical Comparison
REED
RNTX

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: